# FASTinov

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/fastinov-s-a

- Industry: Medical Devices & Equipment
- Headquarters: Porto, Portugal
- Website: www.fastinov.com
- Total disclosed funding: $0.5M
- Latest round: Seed (Sep 29, 2019)
- Investors on record: 2

## About

Based in Portugal, FASTinov focuses on innovative solutions in antimicrobial susceptibility testing, leveraging patented flow cytometry technology to enhance rapid diagnostic capabilities for healthcare providers.Founded in 2013 in Porto, Portugal, FASTinov is dedicated to the development of advanced antimicrobial susceptibility testing solutions. The company has successfully secured funding through two investment rounds, with the latest being a Seed round in June 2022, raising EUR 0.450 mn from Armilar Venture Partners and Bynd Venture Capital. The founders of the company are Acácio Rodrigues, Cidália Pina-Vaz, and Sofia De Oliveira, with Cidália Pina-Vaz currently serving as CEO.FASTinov specializes in the development of ultra-rapid antimicrobial susceptibility testing (AST) solutions utilizing patented flow cytometry technology. The company's flagship product, the FASTinov AST kit, enables healthcare providers to receive antibiograms in under two hours, significantly faster than conventional methods which typically require 24-48 hours. This rapid testing is particularly vital for managing bloodstream infections caused by both Gram-positive and Gram-negative bacteria, facilitating timely antibiotic treatment decisions. The AST kit is complemented by the bioFAST software, which processes flow cytometry data to generate detailed susceptibility reports. FASTinov's products are currently CE-marked for sale in the European Union, catering to hospitals and clinical laboratories, primarily in markets such as Portugal, Spain, and broader European healthcare systems.FASTinov's revenue structure is primarily based on direct sales of its AST kits and associated software to healthcare institutions and laboratories. The company operates a B2B model, engaging directly with medical facilities that require rapid and reliable antimicrobial susceptibility testing solutions. Transactions typically involve the purchase of FASTinov AST kits, which are priced to reflect the advanced technology and quick turnaround provided. The bioFAST software is often bundled with the test kits, enhancing the overall value proposition for clients. The company’s focus on addressing critical healthcare needs positions it strategically within the growing market for rapid diagnostics, emphasizing the importance of its offerings amid rising concerns over antimicrobial resistance.FASTinov intends to utilize the EUR 0.450 mn raised in its most recent funding round to expand its product offerings and enhance its market reach. Plans include the development of new testing products that are designed to further streamline the diagnostic process. Additionally, the company aims to penetrate new geographical markets beyond its current focus in Portugal and Spain, with targeted expansion efforts in broader European regions by the end of 2023. This growth strategy is aimed at meeting the increasing demand for rapid diagnostic solutions in the healthcare sector.

## Funding rounds

- Seed, Sep 29, 2019, $0.5M — Armilar Venture Partners, Bynd Venture Capital

## Investors

- Armilar Venture Partners (https://capitalatlas.ai/funds/armilar-venture-partners) — Seed
- Bynd Venture Capital (https://capitalatlas.ai/funds/bynd-venture-capital) — Seed